The latest edition of the HPRA Drug Safety Newsletter (DSN 111) includes important updates to support the safe and appropriate use of the following medicines:
- Levothyroxine: Biotin interference with thyroid function tests, and drug-drug interaction between levothyroxine and St. John’s Wort and proton-pump inhibitors (PPIs)
- Levonorgestrel-containing products: Factors associated with increased risk of expulsion and update on risks associated with intrauterine exposure
- IMBRUVICA® (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to increased risk of serious cardiac events
- Product information updates recommended by the EMA’s Pharmacovigilance Risk assessment Committee (PRAC)